Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.

Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz B.

Am J Psychiatry. 1993 Nov;150(11):1630-8.

PMID:
8105705
2.

[Medico-economic evaluation of treatment with clozapine versus treatment with previous neuroleptics].

Geronimi-Ferret D, Lesay M, Barges-Bertocchio MH, Cornet-Bonnefont M, Robert H.

Encephale. 1997 Sep;23 Spec No 4:24-31. French.

PMID:
9417402
3.

The pharmacoeconomics of clozapine: a review.

Meltzer HY, Cola PA.

J Clin Psychiatry. 1994 Sep;55 Suppl B:161-5. Review.

PMID:
7961564
4.

[Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].

Bret P, Jolivel C, Bret MC, Veylit S, Martin C, Garcia P.

Encephale. 1998 Jul-Aug;24(4):365-77. French.

PMID:
9809242
5.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

6.

Treatment-resistant schizophrenia--the role of clozapine.

Meltzer HY.

Curr Med Res Opin. 1997;14(1):1-20. Review.

PMID:
9524789
7.
9.

Health status and health care costs for publicly funded patients with schizophrenia started on clozapine.

Blieden N, Flinders S, Hawkins K, Reid M, Alphs LD, Arfken CL.

Psychiatr Serv. 1998 Dec;49(12):1590-3.

PMID:
9856622
10.

Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.

Essock SM, Frisman LK, Covell NH, Hargreaves WA.

Arch Gen Psychiatry. 2000 Oct;57(10):987-94.

PMID:
11015817
11.

[Medical economic impact of schizophrenia].

Martin P.

Encephale. 1995 Jun;21 Spec No 3:67-73. Review. French.

PMID:
7628346
12.

Clozapine for refractory schizophrenia: the Illinois experience.

Buckman RW, Malan RD.

J Clin Psychiatry. 1999;60 Suppl 1:18-22; discussion 28-30.

13.

Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia.

Kelly DL, Feldman S, Boggs DL, Gale E, Conley RR.

Compr Psychiatry. 2010 May-Jun;51(3):298-302. doi: 10.1016/j.comppsych.2009.07.003. Epub 2009 Aug 27.

PMID:
20399340
14.

Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia.

Jonsson D, Wålinder J.

Acta Psychiatr Scand. 1995 Sep;92(3):199-201.

PMID:
7484198
15.

New vs. old antipsychotics: the Texas experience.

Reid WH.

J Clin Psychiatry. 1999;60 Suppl 1:23-5; discussion 28-30.

16.

Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

Rosenheck R, Cramer J, Allan E, Erdos J, Frisman LK, Xu W, Thomas J, Henderson W, Charney D.

Arch Gen Psychiatry. 1999 Jun;56(6):565-72.

PMID:
10359474
17.

Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients.

Meltzer HY, Burnett S, Bastani B, Ramirez LF.

Hosp Community Psychiatry. 1990 Aug;41(8):892-7.

PMID:
2401480
18.

A two-year clinical and economic follow-up of patients on clozapine.

Honigfeld G, Patin J.

Hosp Community Psychiatry. 1990 Aug;41(8):882-5.

PMID:
2401478
19.

Clozapine: current status and role in the pharmacotherapy of schizophrenia.

Remington GJ, Addington D, Collins EJ, Jones BD, Lalonde P, MacCrimmon DJ, MacEwan GW.

Can J Psychiatry. 1996 Apr;41(3):161-6.

PMID:
8722645

Supplemental Content

Support Center